- Home
- Lale Tokgözoğlu
Lale Tokgözoğlu
Haceteppe University, Ankara, Turkey
Biography
S. Lale Tokgözoglu is Professor of Cardiology at Hacettepe University, Ankara, Turkey. She is currently the President of the European Atherosclerosis Society and Deputy Editor of the European Heart Journal. She chaired the ‘Atherosclerosis and Vascular Biology Working Group of the European Society of Cardiology’ between 2008 and 2010. Professor Tokgözoglu has served on the Board of the Turkish Society of Cardiology and was elected to be the first female President of the Society in its history, between 2014-2016. During that time, she worked with the Ministry of Health to develop ‘Heart Health policies’ and strategies. She also chaired the Dyslipidaemia Working Group of the Turkish Society of Cardiology.
Professor Tokgözoglu has contributed to several Guidelines and Consensus Papers on dyslipidaemia and Preventive Cardiology both in Europe and nationally. She was a member of the Steering Committee of the EUROASPIRE studies and has also served on the Board of the Prevention Association as well as different committees of the European Society of Cardiology including the Fellowship and Training Committee, the Education Committee and currently the Research and Grants Committee. She is a member of the Science Academy and a founding member of the Atherosclerosis Research and Education Society in Turkey. She has won the “Prof. Dr. Seref Zileli “Resident of the Year” Award in 1987; the Sandoz Scientific Award in 1989 and the “Young Investigator Award” of the Turkish Society of Cardiology in 1994.
Featured Courses
- 1.00
Published:
Learning objectives
- Recall prevalence of patients who are statin uncontrolled/intolerant
- Define the additive benefit of combination treatment compared with statin intensification
- Name the non-statin LLTs offering proven CV protection
- Identifying patients with indication for novel non-statin therapy
- Initiate lipid-lowering strategies proven to lower future CV events
- 1.00
Published:
Learning objectives
- Assess the current global burden of resistant hypertension
- Carry out appropriate assessments to identify resistant hypertension
- Identify patients most likely to benefit from RDN
- Recall the practical considerations for adopting RDN into routine practice
- Recall the latest data on RDN from recent clinical trials
- 1.00
Published:
Learning objectives
- Discuss the current practice gaps in hypercholesterolaemia management
- Recall best practice for assessing CV risk, defining LDL-C targets and offering patient education
- Stratify patients by CV risk category
- Select cholesterol-lowering therapies according to risk category and LDL-C target